Sahlgrenska University Hospital-ko ikertzaileekin lankidetzan egindako argitalpenak (9)

2020

  1. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

    Blood Cancer Journal, Vol. 10, Núm. 10

2018

  1. Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network

    Leukemia, Vol. 32, Núm. 7, pp. 1542-1560

2017

  1. Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the European myeloma network

    Leukemia, Vol. 2017

2015

  1. Global myeloma research clusters, output, and citations: A bibliometric mapping and clustering analysis

    PLoS ONE, Vol. 10, Núm. 1

2014

  1. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial

    The Lancet Oncology, Vol. 15, Núm. 11, pp. 1195-1206

2013

  1. Plasma cell leukemia: Consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

    Leukemia, Vol. 27, Núm. 4, pp. 780-791

2012

  1. European perspective on multiple myeloma treatment strategies: Update following recent congresses

    Oncologist, Vol. 17, Núm. 5, pp. 592-606

2011

  1. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: Consensus statement

    Leukemia, Vol. 25, Núm. 5, pp. 749-760

2010

  1. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

    Leukemia, Vol. 24, Núm. 6, pp. 1121-1127